MedTrace Logo

Test-retest Reproducibility of [11C]PHNO PET Using the Constant Infusion Paradigm

NCT01699607 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2020-03-06

Study results available
· View outcomes & findings →

Summary

A research study designed to examine amphetamine-induced dopamine release using the PET imaging agent \[11C\]PHNO in tobacco smokers while currently smoking and during acute withdrawal and in nonsmokers. Twenty healthy men and women tobacco smokers and twenty healthy nonsmokers will be recruited. Each subject will participate in 1 MRI and up to 2 \[11C\]PHNO PET scans. On the study day subjects will participate in two \[11C\]PHNO scans (ideally, the two PET scans will be carried out in the same day). Three hours before the second PET scan, amphetamine (0.5 mg/kg, PO) will be administered. In smokers, the scan will occur at 10-21 days of smoking abstinence.

Conditions

  • Nicotine Dependence
  • Healthy

Interventions

DRUG

Amphetamine

All subjects will receive amphetamine to induce elevated dopamine levels in the brain at 0.5mg/kg

Sponsors & Collaborators

  • National Institute of Mental Health (NIMH)

    collaborator NIH

  • National Cancer Institute (NCI)

    collaborator NIH

  • Yale University

    lead OTHER

Principal Investigators

  • Kelly Cosgrove, Ph.D. · Assistant Professor

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-06-30
Primary Completion
2013-07-31
Completion
2013-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01699607 on ClinicalTrials.gov